Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Correction

Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity

Authors: Xiaoge Gao, Pin Jiang, Xiaohuan Wei, Wei Zhang, Jiwei Zheng, Shishuo Sun, Hong Yao, Xiangye Liu, Qing Zhang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Excerpt

Correction: BMC Cancer 23, 154 (2023) …
Literature
1.
Metadata
Title
Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity
Authors
Xiaoge Gao
Pin Jiang
Xiaohuan Wei
Wei Zhang
Jiwei Zheng
Shishuo Sun
Hong Yao
Xiangye Liu
Qing Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10843-0

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma

Research

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study

Research

Developing an evaluation indicators of health literacy for cervical cancer among Chinese women: a modified Delphi method study

Research

Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy

Research

Effect of serum lactate dehydrogenase-to-albumin ratio (LAR) on the short-term outcomes and long-term prognosis of colorectal cancer after radical surgery

Research

TACE sequential MWA guided by cone-beam computed tomography in the treatment of small hepatocellular carcinoma under the hepatic dome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits